📣 Help Shape the Future of UKRI's Gateway to Research (GtR)

We're improving UKRI's Gateway to Research and are seeking your input! Tell us what works, what doesn't, and how we can make GtR more user-friendly, impactful, and effective for the Research and Innovation community. Please send your feedback to gateway@ukri.org by 11 August 2025.

A partially randomised trial of pretomanid, moxifloxacin and pyrazinamide for pulmonary TB. (2021)

First Author: Tweed CD

Attributed to: Tuberculosis Treatment Trials funded by MRC

Abstract

No abstract provided

Bibliographic Information

Digital Object Identifier: http://dx.doi.org/10.5588/ijtld.20.0513

PubMed Identifier: 33762075

Publication URI: http://europepmc.org/abstract/MED/33762075

Type: Journal Article/Review

Volume: 25

Parent Publication: The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease

Issue: 4

ISSN: 1027-3719